Roche moves future Germany investments 'on hold'
Roche said proposed rebate hikes and cost controls have weakened trust, while a planned €600 million Penzberg expansion remains unaffected.
- On Monday, Roche Germany chief Daniel Steiners announced the company has paused all future investment decisions in Germany, citing healthcare cost-cutting policies that have "recently destroyed a lot of trust."
- German lawmakers passed legislation in July requiring a 15.5% rebate on branded medicines, prompting Eli Lilly to halve its planned €2.3 billion investments in June as companies reassess their German footprint.
- Steiners noted a proposed "location clause" would only partially offset the legislative impacts, though Roche confirmed the more than €600 million expansion at its Penzberg site remains unaffected by the review.
- Defending the measures as necessary, Economy Minister Katherina Reiche acknowledged the industry's contributions, while Siemens head Roland Busch warned that companies will invest elsewhere if conditions remain unfavorable.
- Germany's economy has posted little growth since 2022, facing headwinds from US tariffs and international competition as the government hosts a Berlin summit aimed at drumming up business interest.
45 Articles
45 Articles
Roche CEO challenges Germany over its growth strategy: 'We are the industry they need to bet on'
Roche CEO Thomas Schinecker discusses the company's third-quarter earnings and recent expansion in China. He outlines some of the recent pharmaceutical developments the business has made, and explains why they have paused investment in Germany.
The Basel-based drug manufacturer Roche is outraged by the price reductions that the German government is forcing him to do. In the event that Berlin moves back to the pharmaceutical industry, it signals a willingness to compromise.
Friedrich Merz is rolling out the red carpet for international investors in Berlin – and it is precisely the pharmaceutical giant Roche who does not want to make any new investments in Germany. The policy has massively destroyed confidence, complains the Swiss Group and suspends all future investment decisions for the time being. While Schwarz-Rot is overriding the companies with additional burdens, high energy costs, bureaucracy and the billion…
"We have put on pause all future investment decisions in Germany"
"We have put on pause all future investment decisions in Germany"Another illustrative story of German "economic success. " Swiss pharmaceutical giant Roche has suspended investments in the Deutschland economy. In an interview with Die Welt, the head...
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
